Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors.
Eljilany I, Saghand PG, Chen J, Ratan A, McCarter M, Carpten J, Colman H, Ikeguchi AP, Puzanov I, Arnold S, Churchman M, Hwu P, Conejo-Garcia J, Dalton WS, Weiner GJ, El Naqa IM, Tarhini AA. Eljilany I, et al. Among authors: dalton ws. Cancers (Basel). 2023 Oct 10;15(20):4913. doi: 10.3390/cancers15204913. Cancers (Basel). 2023. PMID: 37894280 Free PMC article.
Retraction Notice to: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas.
Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, Chen-Kiang S, Moscinski LC, Seto E, Dalton WS, Wright KL, Sotomayor E, Bhalla K, Tao J. Zhang X, et al. Among authors: dalton ws. Cancer Cell. 2023 Jun 12;41(6):1198. doi: 10.1016/j.ccell.2023.05.003. Cancer Cell. 2023. PMID: 37311416 No abstract available.
Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma.
Mostofa A, Distler A, Meads MB, Sahakian E, Powers JJ, Achille A, Noyes D, Wright G, Fang B, Izumi V, Koomen J, Rampakrishnan R, Nguyen TP, De Avila G, Silva AS, Sudalagunta P, Canevarolo RR, Siqueira Silva MDC, Alugubelli RR, Dai HA, Kulkarni A, Dalton WS, Hampton OA, Welsh EA, Teer JK, Tungesvik A, Wright KL, Pinilla-Ibarz J, Sotomayor EM, Shain KH, Brayer J. Mostofa A, et al. Among authors: dalton ws. JCI Insight. 2021 Dec 22;6(24):e151713. doi: 10.1172/jci.insight.151713. JCI Insight. 2021. PMID: 34793338 Free PMC article.
Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in NSCLC.
Scott JG, Sedor G, Scarborough JA, Kattan MW, Peacock J, Grass GD, Mellon EA, Thapa R, Schell M, Waller A, Poppen S, Andl G, Teer JK, Eschrich SA, Dilling TJ, Dalton WS, Harrison LB, Fox T, Torres-Roca JF. Scott JG, et al. Among authors: dalton ws. J Thorac Oncol. 2021 Mar;16(3):428-438. doi: 10.1016/j.jtho.2020.11.008. Epub 2020 Dec 8. J Thorac Oncol. 2021. PMID: 33301984 Free PMC article.
Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity.
Seligson ND, Warner JL, Dalton WS, Martin D, Miller RS, Patt D, Kehl KL, Palchuk MB, Alterovitz G, Wiley LK, Huang M, Shen F, Wang Y, Nguyen KA, Wong AF, Meric-Bernstam F, Bernstam EV, Chen JL. Seligson ND, et al. Among authors: dalton ws. J Am Med Inform Assoc. 2020 Nov 1;27(11):1808-1812. doi: 10.1093/jamia/ocaa159. J Am Med Inform Assoc. 2020. PMID: 32885823 Free PMC article.
Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease.
Mason MJ, Schinke C, Eng CLP, Towfic F, Gruber F, Dervan A, White BS, Pratapa A, Guan Y, Chen H, Cui Y, Li B, Yu T, Chaibub Neto E, Mavrommatis K, Ortiz M, Lyzogubov V, Bisht K, Dai HY, Schmitz F, Flynt E, Dan Rozelle, Danziger SA, Ratushny A; Multiple Myeloma DREAM Consortium; Dalton WS, Goldschmidt H, Avet-Loiseau H, Samur M, Hayete B, Sonneveld P, Shain KH, Munshi N, Auclair D, Hose D, Morgan G, Trotter M, Bassett D, Goke J, Walker BA, Thakurta A, Guinney J. Mason MJ, et al. Among authors: dalton ws. Leukemia. 2020 Jul;34(7):1866-1874. doi: 10.1038/s41375-020-0742-z. Epub 2020 Feb 14. Leukemia. 2020. PMID: 32060406 Free PMC article.
BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models.
Zhao X, Ren Y, Lawlor M, Shah BD, Park PMC, Lwin T, Wang X, Liu K, Wang M, Gao J, Li T, Xu M, Silva AS, Lee K, Zhang T, Koomen JM, Jiang H, Sudalagunta PR, Meads MB, Cheng F, Bi C, Fu K, Fan H, Dalton WS, Moscinski LC, Shain KH, Sotomayor EM, Wang GG, Gray NS, Cleveland JL, Qi J, Tao J. Zhao X, et al. Among authors: dalton ws. Cancer Cell. 2019 May 13;35(5):752-766.e9. doi: 10.1016/j.ccell.2019.04.005. Cancer Cell. 2019. PMID: 31085176 Free PMC article.
PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.
Ren Y, Bi C, Zhao X, Lwin T, Wang C, Yuan J, Silva AS, Shah BD, Fang B, Li T, Koomen JM, Jiang H, Chavez JC, Pham LV, Sudalagunta PR, Wan L, Wang X, Dalton WS, Moscinski LC, Shain KH, Vose J, Cleveland JL, Sotomayor EM, Fu K, Tao J. Ren Y, et al. Among authors: dalton ws. J Clin Invest. 2018 Dec 3;128(12):5517-5530. doi: 10.1172/JCI122533. Epub 2018 Nov 5. J Clin Invest. 2018. PMID: 30260324 Free PMC article.
Optimizing Cancer Treatment Using Game Theory: A Review.
Stanková K, Brown JS, Dalton WS, Gatenby RA. Stanková K, et al. Among authors: dalton ws. JAMA Oncol. 2019 Jan 1;5(1):96-103. doi: 10.1001/jamaoncol.2018.3395. JAMA Oncol. 2019. PMID: 30098166 Free PMC article. Review.
220 results